Mitsubishi Tanabe reports lower Q3 net income, provides annual outlook

Mitsubishi Tanabe Pharma Corporation, a Japan-based pharmaceutical company, has reported that net income for the nine months ended December 31, 2012 was JPY35.25 billion, or JPY62.83 per share, compared to JPY35.85 billion, or JPY63.9 per share, for the same period ended December 31, 2011. The company expects net income of JPY40.5 billion and net income per share of JPY72.19 for the fiscal year ending March 31, 2013.

Net sales for the nine months ended December 31, 2012 were JPY322.57 billion, compared to JPY315.75 billion for the same period ended December 31, 2011.

Gross profit for the nine months ended December 31, 2012 was JPY195.84 billion, compared to JPY196.42 billion for the same period ended December 31, 2011.

Operating income for the nine months ended December 31, 2012 was JPY58.86 billion, compared to JPY59.94 billion for the same period ended December 31, 2011.

Ordinary income for the third quarter ended December 31, 2012 was JPY60.14 billion, compared to JPY60.39 billion for the same period ended December 31, 2011.

The company expects net sales of JPY425 billion and operating income of JPY70 billion for the fiscal year ending March 31, 2013.